Trial Profile
A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody for the lntraoperative Detection of Neoplastic Lesions in Patients with Cancer of the Rectum or Pancreas
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Feb 2019
Price :
$35
*
At a glance
- Drugs SGM 101 (Primary)
- Indications Pancreatic cancer; Rectal cancer
- Focus Adverse reactions
- 12 May 2016 New trial record